دورية أكاديمية

Beneficial effects of simultaneously targeting calorie intake and calorie efficiency in diet-induced obese mice.

التفاصيل البيبلوغرافية
العنوان: Beneficial effects of simultaneously targeting calorie intake and calorie efficiency in diet-induced obese mice.
المؤلفون: Sing-Young Chen, Telfser, Aiden J., Olzomer, Ellen M., Vancuylenberg, Calum S., Mingyan Zhou, Beretta, Martina, Li, Catherine, Alexopoulos, Stephanie J., Turner, Nigel, Byrne, Frances L., Santos, Webster L., Hoehn, Kyle L.
المصدر: Clinical Science; 2/15/2024, Vol. 138 Issue 4, p173-187, 15p
مصطلحات موضوعية: ANTIOBESITY agents, WEIGHT loss, WESTERN diet, LEAN body mass, GASTRIC emptying
مستخلص: Semaglutide is an anti-diabetes and weight loss drug that decreases food intake, slows gastric emptying, and increases insulin secretion. Patients begin treatment with low-dose semaglutide and increase dosage over time as efficacy plateaus. With increasing dosage, there is also greater incidence of gastrointestinal side effects. One reason for the plateau in semaglutide efficacy despite continued low food intake is due to compensatory actions whereby the body becomes more metabolically efficient to defend against further weight loss. Mitochondrial uncoupler drugs decrease metabolic efficiency, therefore we sought to investigate the combination therapy of semaglutide with the mitochondrial uncoupler BAM15 in diet-induced obese mice. Mice were fed high-fat western diet (WD) and stratified into six treatment groups including WD control, BAM15, low-dose semaglutide without or with BAM15, and high-dose semaglutide without or with BAM15. Combining BAM15 with either semaglutide dose decreased body fat and liver triglycerides, which was not achieved by any monotherapy, while high-dose semaglutide with BAM15 had the greatest effect on glucose homeostasis. This study demonstrates a novel approach to improve weight loss without loss of lean mass and improve glucose control by simultaneously targeting energy intake and energy efficiency. Such a combination may decrease the need for semaglutide dose escalation and hence minimize potential gastrointestinal side effects. [ABSTRACT FROM AUTHOR]
Copyright of Clinical Science is the property of Portland Press Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:01435221
DOI:10.1042/CS20231016